Amiselimod hydrochloride is primarily used in the field of immunology and neurology for its therapeutic potential in treating autoimmune diseases and inflammatory conditions. It functions as a sphingosine-1-phosphate receptor modulator, which helps regulate the immune system by preventing the migration of lymphocytes from lymph nodes into the bloodstream. This mechanism is particularly beneficial in managing conditions such as multiple sclerosis, where it reduces the frequency of relapses and slows disease progression. Additionally, it is being investigated for its efficacy in other autoimmune disorders like Crohn's disease and ulcerative colitis. Its ability to modulate immune responses while maintaining a favorable safety profile makes it a promising candidate for long-term treatment strategies in chronic inflammatory diseases.